Project Grant R01DA063181
Award Date
6/1/25
Completion Date
4/30/30
Dollars Obligated
$805K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award, totaling $1,481,760 and provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to investigate how methamphetamine (MA) use promotes immune dysfunction in people living with HIV (PWH) even during antiretroviral therapy (ART) suppression. The research aims to determine how MA-induced activation of the NLRP3 inflammasome leads to altered metabolism, epigenetics, and immune dysfunction in T...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), will support research to spatially characterize HIV-host cellular interactions in the central nervous system (CNS) of people with HIV (PWH) who died suddenly. The $983,672 award will fund the development and implementation of innovative single-cell and spatial genomic assays to analyze the localization, distribution, and activity of HIV-infected...
The National Institute on Drug Abuse (NIDA) awarded a $2,223,769 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of California, San Diego (UCSD) to investigate the individual and combined impact of HIV and opioids on inflammasome-mediated neuroinflammation and neurotoxicity. The 5-year study, which commenced on April 15, 2025, aims to uncover the mechanistic intersection between HIV and opioids that leads to more severe neurological...
This federal Project Grant award for $263,119 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) is focused on developing NLRP3 inhibitors to address HIV-associated neuroinflammation in cocaine use. The key objectives are to computationally design, synthesize, and screen novel analogues of a lead compound, AMS-17, to improve its biological activity and maintain low toxicity. The project involves in vitro and in vivo screening of...
The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), has awarded a $1,372,480 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the Board of Regents of the University of Nebraska's University of Nebraska Medical Center (UNMC) division. The 5-year grant, effective April 15, 2025 through January 31, 2030, will fund research to elucidate the molecular mechanisms by which the interplay of HIV transactivator of transcription...
This $1,454,724 Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), aims to understand the mechanisms involved in HIV-1 latency in the central nervous system (CNS). The primary objectives are to identify key factors, pathways, and regulators that determine the establishment, maintenance, and reactivation of latent HIV-1 virus in brain myeloid cell lineages, such as microglia and macrophages. The research will...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $157,568 to Drexel University to elucidate corticolimbic circuit and neuroimmune mechanisms underlying HIV-induced dysregulation of reward-seeking behavior. The research aims to use optogenetic and chemogenetic techniques to stimulate the infralimbic cortex-nucleus accumbens shell circuit and modulate microglial function to rescue HIV-induced...
The J. David Gladstone Institutes received a $687,416 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research aimed at developing latency-promoting agents (LPAs) that can suppress the HIV transcriptionally active reservoir and lock HIV in a silenced state, even in the presence of addictive substances. The research combines expertise in HIV biology and targeted kinase inhibition to advance...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $502,861 to the University of California, San Diego (UCSD) to investigate the role of the PCIF1 protein and its effects on RNA modification in the context of HIV infection. The key objectives are to: Define the dynamics and mapping of human m6Am RNA methylome in response to HIV infection and methamphetamine exposure....
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $1,032,192 to Yale University to conduct research on the cell-type specific epigenomic effects of cannabis use in people living with HIV. The project aims to dissect the interactions between HIV infection and cannabis use, and identify potential druggable targets through comprehensive profiling of DNA methylation across different cell types. The...